Boehringer Ingelheim, Topas Launch Antigen-Specific Tolerance Induction Partnership

Boehringer Ingelheim will partner with Topas Therapeutics to develop virus-based vectors designed to deliver therapeutics, in the initial phase of a broader collaboration aimed at tackling anti-drug antibodies (ADAs) by focusing on antigen-specific tolerance induction.Under a multi-year collaboration and option agreement whose value was not disclosed, Topas agreed to oversee the design, application and production of its proprietary tolerizing particles while Boehringer Ingelheim agreed to contri